Under the pact, both the companies will evaluate whether a fixed ratio of pramlintide and insulin can effectively help treat type 1 diabetes.
The program will also evaluate the optimal pramlintide: insulin dose ratios, and determine whether delivering pramlintide and insulin in this fixed ratio, can improve glucose control and optimize treatment of type 1 diabetes compared with insulin alone.
JDRF Treatment Therapies assistant vice president Aaron Kowalski said the study of this combination therapy is exciting because, if successful, it could potentially help patients achieve tighter glucose control without increasing treatment complexity.
"Successfully co-formulating pramlintide and insulin could potentially help people living with type 1 diabetes to better, and more conveniently, control their disease," Kowalski said.